MLYS
Mineralys Therapeutics, Inc.
26.60$
-1.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | – | – | – | – | +37.2% | |
| – | +7,900.0% | +468.8% | +1,012.1% | +124.0% | +70.5% | |
| – | +58.2% | -125.4% | – | – | – | |
| – | +751.0% | -81.1% | -1,067.6% | – | -71.3% | |
| – | – | – | – | – | -84.4% | |
| – | +0.0% | +0.0% | +637.5% | – | -439.0% | |
| – | – | – | – | – | – | |
| – | – | – | – | +245.3% | +10.0% | |
| – | -100.0% | – | – | – | – | |
| – | +521.7% | +437.6% | +58.8% | -42.9% | +408.9% | |
| – | +556.7% | +732.6% | -149.8% | – | -9.2% | |
| – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.